Literature DB >> 34281904

Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.

Maria Laura Acosta Felquer1, Luciano LoGiudice1, Maria Laura Galimberti2, Javier Rosa1, Luis Mazzuoccolo2, Enrique R Soriano3.   

Abstract

OBJECTIVES: To compare the incidence of psoriatic arthritis (PsA) in patients with psoriasis (PsO) according to different treatments for their skin: topics/no treatment, conventional disease-modifying antirheumatic drugs (DMARDs) (cDMARDs) or biological DMARDs (bDMARDs).
METHODS: Patients with PsO without PsA followed at a university hospital were included in this retrospective cohort study. Patients were classified according to their treatment in topics (topics, phototherapy or no treatment), cDMARDs (methotrexate and cyclosporine) and bDMARDs (tumour necrosis factor inhibitors (TNFi), interleukin 17 inhibitors (IL-17i) and IL-12-23i ((interleukin (IL) 12/IL-23 inhibitor))) groups. Incident cases of PsA were attributed to one treatment if developed during the administration of that treatment. A Cox proportional hazards model was used to evaluate the adjusted risk of PsA development by treatment group.
RESULTS: 1719 patients with PsO contributed a total of 14 721 patient/years (py). 1387 (81%) patients were in the topics, 229 (13%) in cDMARDs and 103 (6%) in the bDMARDs group. During follow-up, 239 patients (14%) developed PsA (231 under topics, six under cDMARDs and two under bDMARDs). Global incidence was 1.6 per 100 py. The risk of developing PsA in patients with PsO treated with bDMARDs was significantly lower (incidence rate ratio (IRR)=0.26; 95% CI 0.03 to 0.94; p=0.0111), compared with topics, but not compared with cDMARDs (IRR=0.35; 95% CI 0.035 to 1.96; p=0.1007). Adjusted Cox proportional hazards regression analysis showed that male sex, nail involvement and higher body max index were associated with increased risk of developing PsA, while biologics use was protective (HR: 0.19; 95% CI 0.05 to 0.81).
CONCLUSION: Treatment with biologics in patients with PsO reduced the risk of PsA development. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biological therapy; epidemiology; psoriatic arthritis

Mesh：

Substances：

Year:  2021        PMID： 34281904     DOI： 10.1136/annrheumdis-2021-220865

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  8 in total

1.  Does psoriasis treatment affect PsA development?

Authors:  Joseph F Merola; Alexis Ogdie
Journal:  Nat Rev Rheumatol       Date:  2021-12       Impact factor: 20.543

2.  The Challenge Arising from New Knowledge about Immune and Inflammatory Skin Diseases: Where We Are Today and Where We Are Going.

Authors:  Anna Campanati; Emanuela Martina; Annamaria Offidani
Journal:  Biomedicines       Date:  2022-04-20

Review 3.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.

Authors:  Laura C Coates; Enrique R Soriano; Nadia Corp; Heidi Bertheussen; Kristina Callis Duffin; Cristiano B Campanholo; Jeffrey Chau; Lihi Eder; Daniel G Fernández-Ávila; Oliver FitzGerald; Amit Garg; Dafna D Gladman; Niti Goel; Philip S Helliwell; M Elaine Husni; Deepak R Jadon; Arnon Katz; Dhruvkumar Laheru; John Latella; Ying-Ying Leung; Christine Lindsay; Ennio Lubrano; Luis Daniel Mazzuoccolo; Philip J Mease; Denis O'Sullivan; Alexis Ogdie; Wendy Olsder; Penelope Esther Palominos; Lori Schick; Ingrid Steinkoenig; Maarten de Wit; D A van der Windt; Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2022-06-27       Impact factor: 32.286

4.  Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.

Authors:  Francesco Bellinato; Paolo Gisondi; Elena Mason; Paolo Ricci; Martina Maurelli; Giampiero Girolomoni
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-27

5.  Psoriatic arthritis among Egyptian patients with psoriasis attending the dermatology clinic: prevalence, comorbidities, and clinical predictors.

Authors:  Ayman El-Garf; Doaa Ahmed Teleb; Eman R Said; Mervat Eissa
Journal:  Reumatologia       Date:  2022-01-05

Review 6.  Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis.

Authors:  Alen Zabotti; Orazio De Lucia; Garifallia Sakellariou; Alberto Batticciotto; Gilberto Cincinelli; Ivan Giovannini; Luca Idolazzi; Gabriella Maioli; Ilaria Tinazzi; Daniel Aletaha; Salvatore De Vita; Antonio Marchesoni; Josef Smolen; Annamaria Iagnocco; Dennis McGonagle; Roberto Caporali
Journal:  Rheumatol Ther       Date:  2021-10-01

Review 7.  Diagnosis and Intervention in Early Psoriatic Arthritis.

Authors:  Tomoyuki Hioki; Mayumi Komine; Mamitaro Ohtsuki
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

Review 8.  Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis.

Authors:  Paolo Gisondi; Francesco Bellinato; Martina Maurelli; Davide Geat; Alen Zabotti; Dennis McGonagle; Giampiero Girolomoni
Journal:  Psoriasis (Auckl)       Date:  2022-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.